|
US5879680A
(en)
|
1987-12-23 |
1999-03-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cloned DNA for synthesizing unique glucocerebrosidase
|
|
WO1998009524A1
(en)
*
|
1996-09-06 |
1998-03-12 |
Chiron Corporation |
Methods and compositions for liver specific delivery of therapeutic molecules using recombinant aav vectors
|
|
EP1112090A2
(en)
|
1998-09-09 |
2001-07-04 |
Myelos Corporation |
Method of stimulating prosaposin receptor activity
|
|
EP1121429A2
(en)
|
1998-10-16 |
2001-08-08 |
Introgene B.V. |
Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e
|
|
AU780231B2
(en)
|
1998-11-10 |
2005-03-10 |
University Of North Carolina At Chapel Hill, The |
Virus vectors and methods of making and administering the same
|
|
US6696272B1
(en)
|
1999-06-02 |
2004-02-24 |
Hsc Research & Development Limited Partnership |
Products and methods for gaucher disease therapy
|
|
AU5323301A
(en)
|
2000-04-06 |
2001-10-23 |
Kos Pharma Inc |
Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
|
|
GB0009887D0
(en)
*
|
2000-04-20 |
2000-06-07 |
Btg Int Ltd |
Cytotoxic agents
|
|
US7056502B2
(en)
|
2000-04-28 |
2006-06-06 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
|
|
JP2004516016A
(ja)
|
2000-09-18 |
2004-06-03 |
ジェンザイム・コーポレイション |
ハイブリッドユビキチンプロモーターを含む発現ベクター
|
|
US7232670B2
(en)
|
2001-09-28 |
2007-06-19 |
St. Jude Children's Research Hospital |
Targeting proteins to cells expressing mannose receptors via expression in insect cells
|
|
MX359371B
(es)
*
|
2001-11-13 |
2018-09-25 |
Univ Pennsylvania |
Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
|
|
US20030133924A1
(en)
|
2001-12-21 |
2003-07-17 |
Novazyme Pharmaceuticals, Inc. |
Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
|
|
AU2003221733A1
(en)
|
2002-04-17 |
2003-11-03 |
University Of Florida Research Foundation, Inc. |
Improved raav vectors
|
|
EP1620133B1
(en)
|
2003-05-01 |
2015-12-09 |
Genzyme Corporation |
Gene therapy for neurometabolic disorders
|
|
WO2006036465A2
(en)
|
2004-09-03 |
2006-04-06 |
University Of Florida |
Compositions and methods for treating cystic fibrosis
|
|
CA2580189C
(en)
|
2004-09-29 |
2013-05-21 |
Children's Memorial Hospital |
Sirna-mediated gene silencing of alpha synuclein
|
|
AU2006254796B2
(en)
|
2005-06-08 |
2012-08-16 |
Amicus Therapeutics, Inc. |
Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
|
|
GB0605337D0
(en)
|
2006-03-17 |
2006-04-26 |
Genomica Sau |
Treatment of CNS conditions
|
|
EP2687223B2
(en)
|
2006-05-30 |
2024-11-20 |
Mayo Foundation For Medical Education And Research |
Detecting and treating dementia
|
|
US8486635B2
(en)
|
2006-05-30 |
2013-07-16 |
Mayo Foundation For Medical Education And Research |
Detecting and treating dementia
|
|
HUE031156T2
(en)
|
2006-06-07 |
2017-06-28 |
Genzyme Corp |
Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
|
|
EP2145014B1
(en)
*
|
2007-04-05 |
2012-12-12 |
The J. David Gladstone Institutes |
Agents that reduce neuronal overexcitation
|
|
WO2008143797A1
(en)
|
2007-05-11 |
2008-11-27 |
Genzyme Corporation |
Methods of producing a secreted protein
|
|
EP2154969B1
(en)
|
2007-05-16 |
2015-11-18 |
The Brigham and Women's Hospital, Inc. |
Treatment of synucleinopathies
|
|
US20090176729A1
(en)
*
|
2007-12-14 |
2009-07-09 |
Alnylam Pharmaceuticals, Inc. |
Method of treating neurodegenerative disease
|
|
WO2009089635A1
(en)
|
2008-01-16 |
2009-07-23 |
Neurodyn, Inc. |
Treating neurodegenerative diseases with progranulin (pgrn)
|
|
US9265843B2
(en)
|
2008-03-27 |
2016-02-23 |
The Ohio State University |
Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
|
|
HRP20250897T1
(hr)
|
2009-05-02 |
2025-09-26 |
Genzyme Corporation |
Genska terapija za neurodegenerativne poremećaje
|
|
US9255266B2
(en)
*
|
2009-05-06 |
2016-02-09 |
Rutgers, The State University Of New Jersey |
RNA targeting in alpha-synucleinopathies
|
|
EP2561073B1
(en)
|
2010-04-23 |
2016-08-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
US9290759B2
(en)
|
2010-08-25 |
2016-03-22 |
The Trustees Of Columbia University In The City Of New York |
Optimized miRNA constructs
|
|
WO2012027713A2
(en)
*
|
2010-08-26 |
2012-03-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of snca
|
|
WO2012057363A1
(ja)
*
|
2010-10-27 |
2012-05-03 |
学校法人自治医科大学 |
神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
|
JP6312436B2
(ja)
|
2010-11-16 |
2018-04-18 |
ニューロダイン ライフ サイエンシズ インコーポレイテッドＮｅｕｒｏｄｙｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． |
ネプリライシンの発現および活性を増大させるための方法および医薬組成物
|
|
GB201103062D0
(en)
*
|
2011-02-22 |
2011-04-06 |
Isis Innovation |
Method
|
|
DK3081568T3
(da)
|
2011-05-09 |
2020-02-24 |
Eip Pharma Llc |
Sammensætninger og fremgangsmåder til behandling af alzheimers sygdom
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
CN104540952A
(zh)
|
2012-05-18 |
2015-04-22 |
衣阿华大学研究基金会 |
用于治疗淀粉状蛋白沉积的方法和组合物
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
AU2013337354A1
(en)
|
2012-11-05 |
2015-05-21 |
Genzyme Corporation |
Compositions and methods for treating proteinopathies
|
|
WO2014168953A1
(en)
*
|
2013-04-08 |
2014-10-16 |
University Of Iowa Research Foundation |
Chimeric adeno-associated virus/ bocavirus parvovirus vector
|
|
CN115120746A
(zh)
|
2013-05-15 |
2022-09-30 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
|
US9347107B2
(en)
|
2013-05-23 |
2016-05-24 |
Norman Z Lai |
Vector containing multiple nucleotide sequences for the expression of enzymes
|
|
US9951330B2
(en)
|
2013-07-11 |
2018-04-24 |
The Trustees Of Columbia University In The City Of New York |
Micrornas that silence tau expression
|
|
US9574184B2
(en)
|
2013-09-25 |
2017-02-21 |
Children's Hospital Medical Center |
Lysosomal protein targeting sequence and therapeutic applications of same
|
|
CN105745326A
(zh)
|
2013-10-24 |
2016-07-06 |
优尼科Ip有限公司 |
用于基因治疗神经疾病的aav-5假型载体
|
|
GB201403260D0
(en)
*
|
2014-02-25 |
2014-04-09 |
Univ Manchester |
Treatment of retinal degeneration using gene therapy
|
|
MA40460A
(fr)
|
2014-08-11 |
2016-02-18 |
Shire Human Genetic Therapies |
Ciblage lysosomial et utilisation correspondante
|
|
RU2716991C2
(ru)
*
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
|
US10900053B2
(en)
|
2014-11-21 |
2021-01-26 |
University Of Florida Research Foundation, Incorporated |
Genome-modified recombinant adeno-associated virus vectors
|
|
US10513701B2
(en)
*
|
2015-03-25 |
2019-12-24 |
Università Degli Studi Di Trento |
RNA interference mediated therapy for neurodegenerative diseases
|
|
US20170035860A1
(en)
|
2015-04-02 |
2017-02-09 |
Alexander C. Flynn |
Compositions and methods for treatment of neurogenerative diseases
|
|
EP3285788B1
(en)
|
2015-04-23 |
2024-12-18 |
University of Massachusetts |
Modulation of aav vector transgene expression
|
|
CA2985235A1
(en)
*
|
2015-05-07 |
2016-11-10 |
Shire Human Genetic Therapies, Inc. |
Glucocerebrosidase gene therapy for parkinson's disease
|
|
EP3091087A1
(en)
|
2015-05-08 |
2016-11-09 |
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol |
Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts
|
|
HK1256341A1
(zh)
|
2015-05-15 |
2019-09-20 |
明尼苏达大学董事会 |
用於治疗性递送到中枢神经系统的腺相关物
|
|
MX2018004755A
(es)
|
2015-10-29 |
2018-12-19 |
Voyager Therapeutics Inc |
Entrega de polinucleotidos dirigidos al sistema nervioso central.
|
|
SG11201802408RA
(en)
|
2015-11-05 |
2018-05-30 |
Bamboo Therapeutics Inc |
Modified friedreich ataxia genes and vectors for gene therapy
|
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
EP3411484B1
(en)
|
2016-02-05 |
2023-10-04 |
Emory University |
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
|
|
WO2017147509A1
(en)
|
2016-02-25 |
2017-08-31 |
Marco Colonna |
Compositions comprising trem2 and methods of use thereof
|
|
US20190328906A1
(en)
|
2016-03-02 |
2019-10-31 |
The Children's Hospital Of Philadelphia |
Therapy for frontotemporal dementia
|
|
EP3808849A1
(en)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CN112501208A
(zh)
|
2017-10-03 |
2021-03-16 |
普利维尔治疗公司 |
用于溶酶体障碍的基因疗法
|
|
BR112020006661A2
(pt)
|
2017-10-03 |
2020-10-13 |
Prevail Therapeutics, Inc. |
terapias de genes para distúrbios lipossomais
|
|
AU2018346104B2
(en)
|
2017-10-03 |
2023-07-27 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
|
BR112020008033A2
(pt)
|
2017-10-23 |
2020-10-27 |
Prevail Therapeutics, Inc. |
terapias gênicas para doença neurodegenerativa
|
|
US20200283800A1
(en)
|
2017-10-23 |
2020-09-10 |
Prevail Therapeutics, Inc. |
Gene therapies for neurodegenerative diseases
|
|
JP7616995B2
(ja)
|
2018-11-28 |
2025-01-17 |
プリベイル セラピューティクス，インコーポレーテッド |
神経変性疾患のための遺伝子治療
|
|
WO2020210615A1
(en)
|
2019-04-10 |
2020-10-15 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
|
US20220211871A1
(en)
|
2019-04-10 |
2022-07-07 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
|
CA3136004A1
(en)
|
2019-04-10 |
2020-10-15 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
|
JP7664848B2
(ja)
|
2019-04-10 |
2025-04-18 |
プリベイル セラピューティクス，インコーポレーテッド |
リソソーム障害のための遺伝子療法
|